Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmatics

Allergy. 2010 Nov;65(11):1495-6. doi: 10.1111/j.1398-9995.2010.02403.x.

Authors

E Pace¹, M Ferraro, A Bruno, J Bousquet, M Gjomarkaj

Affiliation

¹ Istituto di Biomedicina e Immunologia Molecolare, Consiglio Nazionale delle Ricerche, Via Ugo La Malfa, 153, 90146 Palermo, Italy. pace@ibim.cnr.it

PMID: 20486917
DOI: 10.1111/j.1398-9995.2010.02403.x

No abstract available

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Asthma / drug therapy*
Asthma / immunology
Asthma / metabolism*
Blotting, Western
Clinical Trials as Topic
Cyclic AMP Response Element-Binding Protein / drug effects
Forced Expiratory Volume
Forkhead Transcription Factors / biosynthesis
Forkhead Transcription Factors / drug effects
Humans
Immunohistochemistry
Inflammation / drug therapy
Interleukin-8 / biosynthesis
Interleukin-8 / drug effects
Omalizumab
Time

Substances

Anti-Asthmatic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cyclic AMP Response Element-Binding Protein
FOXP3 protein, human
Forkhead Transcription Factors
Interleukin-8
Omalizumab